-
Opiant Pharmaceuticals Inc (NASDAQ: OPNT) shares
surged 20.9 percent to $ 33.42.
-
AeroVironment, Inc. (NASDAQ: AVAV) shares jumped
19.5 percent to $47.02 after the company posted better-than-expected quarterly results.
-
New Age Beverages Corp (NASDAQ: NBEV) shares
gained 15.5 percent to $3.96 as the company reported the expansion of Marley yerba Mate™.
-
Caleres Inc (NYSE: CAL) shares rose 10.6 percent to
$27.45 as the company reported stronger-than-expected results for its second quarter.
-
Universal Display Corporation (NASDAQ: OLED)
shares jumped 9.2 percent to $121.25. Deutsche Bank initiated coverage on Universal Display with a Buy rating and a $135.00
price target.
-
Bob Evans Farms Inc (NASDAQ: BOBE) shares gained
8.9 percent to $69.67. Bob Evans Farms posted in-line quarterly earnings, while sales exceeded estimates. The company also
raised its FY18 outlook.
-
Intra-Cellular Therapies Inc (NASDAQ: ITCI)
climbed 8.5 percent to $17.25. Ladenburg Thalmann upgraded Intra-Cellular Therapies from Neutral to Buy.
-
Mazor Robotics Ltd - ADR (NASDAQ: MZOR) surged
8.1 percent to $45.35 following announcement of Medtronic making a $40 million third tranche investment in the company.
-
Aluminum Corp. of China Limited (ADR) (NYSE: ACH)
shares climbed 6.2 percent to $18.59 after gaining 1.45 percent on Tuesday.
-
Vericel Corp (NASDAQ: VCEL) shares rose 5.4
percent to $4.32.
-
Analog Devices, Inc. (NASDAQ: ADI) gained 5.2
percent to $83.68 after the company posted upbeat quarterly earnings.
-
Reata Pharmaceuticals Inc (NASDAQ: RETA) surged 4
percent to $28.94. Jefferies initiated coverage on Reata Pharmaceuticals with a Buy rating.
-
Cae Inc (USA) (NYSE: CAE) shares rose 3.8 percent to
$16.55. BMO Capital upgraded Cae from Market Perform to Outperform.
-
Momo Inc (ADR) (NASDAQ: MOMO) gained 2.6 percent
to $34.94. Standpoint Research initiated coverage of Momo with a Buy rating.
-
C.H. Robinson Worldwide Inc (NASDAQ: CHRW) rose
2.5 percent to $72.85. Stephens upgraded C.H. Robinson from Equal Weight to Overweight.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.